Principles of Immunotherapy in Non-Small Cell Lung Cancer

Melinda L. Hsu; Jarushka Naidoo

doi:10.1016/j.thorsurg.2020.01.009

Principles of Immunotherapy in Non-Small Cell Lung Cancer

Melinda L. Hsu, Jarushka Naidoo

School of Medicine

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Immunotherapy has transformed the treatment of many tumors. Robust data demonstrating improved overall survival and progression-free survival in patients treated with monoclonal antibodies have established immune checkpoint inhibitors as standard of care in stages III and IV non-small cell lung cancer. Nivolumab is effective in previously treated patients with metastatic non-small cell lung cancer. Pembrolizumab and atezolizumab are approved as monotherapy and in combination with other therapies. Ongoing trials investigate the potential role of immunotherapy in earlier disease settings. Identifying predictive biomarkers of response will further amplify the impact of immune checkpoint inhibitors in the treatment of non-small cell lung cancer.

Original language	English (US)
Pages (from-to)	187-198
Number of pages	12
Journal	Thoracic surgery clinics
Volume	30
Issue number	2
DOIs	https://doi.org/10.1016/j.thorsurg.2020.01.009
State	Published - May 1 2020

Keywords

Anti-PD-1
Anti-PD-L1
Immune checkpoint inhibitors
Immunotherapy
Non-small cell lung cancer

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/j.thorsurg.2020.01.009

Cite this

@article{05696a41dd4240c5b0dd78edd38ba3f4,

title = "Principles of Immunotherapy in Non-Small Cell Lung Cancer",

abstract = "Immunotherapy has transformed the treatment of many tumors. Robust data demonstrating improved overall survival and progression-free survival in patients treated with monoclonal antibodies have established immune checkpoint inhibitors as standard of care in stages III and IV non-small cell lung cancer. Nivolumab is effective in previously treated patients with metastatic non-small cell lung cancer. Pembrolizumab and atezolizumab are approved as monotherapy and in combination with other therapies. Ongoing trials investigate the potential role of immunotherapy in earlier disease settings. Identifying predictive biomarkers of response will further amplify the impact of immune checkpoint inhibitors in the treatment of non-small cell lung cancer.",

keywords = "Anti-PD-1, Anti-PD-L1, Immune checkpoint inhibitors, Immunotherapy, Non-small cell lung cancer",

author = "Hsu, {Melinda L.} and Jarushka Naidoo",

year = "2020",

month = may,

day = "1",

doi = "10.1016/j.thorsurg.2020.01.009",

language = "English (US)",

volume = "30",

pages = "187--198",

journal = "Thoracic surgery clinics",

issn = "1547-4127",

publisher = "W.B. Saunders",

number = "2",

}

TY - JOUR

T1 - Principles of Immunotherapy in Non-Small Cell Lung Cancer

AU - Hsu, Melinda L.

AU - Naidoo, Jarushka

PY - 2020/5/1

Y1 - 2020/5/1

N2 - Immunotherapy has transformed the treatment of many tumors. Robust data demonstrating improved overall survival and progression-free survival in patients treated with monoclonal antibodies have established immune checkpoint inhibitors as standard of care in stages III and IV non-small cell lung cancer. Nivolumab is effective in previously treated patients with metastatic non-small cell lung cancer. Pembrolizumab and atezolizumab are approved as monotherapy and in combination with other therapies. Ongoing trials investigate the potential role of immunotherapy in earlier disease settings. Identifying predictive biomarkers of response will further amplify the impact of immune checkpoint inhibitors in the treatment of non-small cell lung cancer.

AB - Immunotherapy has transformed the treatment of many tumors. Robust data demonstrating improved overall survival and progression-free survival in patients treated with monoclonal antibodies have established immune checkpoint inhibitors as standard of care in stages III and IV non-small cell lung cancer. Nivolumab is effective in previously treated patients with metastatic non-small cell lung cancer. Pembrolizumab and atezolizumab are approved as monotherapy and in combination with other therapies. Ongoing trials investigate the potential role of immunotherapy in earlier disease settings. Identifying predictive biomarkers of response will further amplify the impact of immune checkpoint inhibitors in the treatment of non-small cell lung cancer.

KW - Anti-PD-1

KW - Anti-PD-L1

KW - Immune checkpoint inhibitors

KW - Immunotherapy

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85084030615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084030615&partnerID=8YFLogxK

U2 - 10.1016/j.thorsurg.2020.01.009

DO - 10.1016/j.thorsurg.2020.01.009

M3 - Review article

C2 - 32327177

AN - SCOPUS:85084030615

SN - 1547-4127

VL - 30

SP - 187

EP - 198

JO - Thoracic surgery clinics

JF - Thoracic surgery clinics

IS - 2

ER -

Principles of Immunotherapy in Non-Small Cell Lung Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this